Mereo BioPharma (MREO) Free Cash Flow (2023 - 2026)

Mereo BioPharma (MREO) has reported Free Cash Flow for 4 consecutive years, with -$4.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 48.35% year-over-year to -$4.3 million; the TTM figure through Mar 2026 stood at -$27.0 million (up 18.79% YoY), while the FY2025 annual figure was -$31.0 million, up 5.61% from the prior year.
• Free Cash Flow climbed to -$4.3 million in Q1 2026 per MREO's latest filing, from -$7.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $2.7 million in Q3 2023 and bottomed at -$9.4 million in Q4 2024.
• Historically, Free Cash Flow has averaged -$6.8 million across 4 years, with a median of -$7.7 million in 2025.
• Annual changes were most pronounced in 2024 — Free Cash Flow plunged 382.78% — and 2026, when it jumped 48.35%.
• Mereo BioPharma's Free Cash Flow stood at -$6.8 million in 2023, then plunged by 38.75% to -$9.4 million in 2024, then rose by 18.45% to -$7.7 million in 2025, then jumped by 43.87% to -$4.3 million in 2026.
• Business Quant data shows MREO's Free Cash Flow at -$4.3 million in Q1 2026, -$7.7 million in Q4 2025, and -$7.3 million in Q3 2025.